XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information - $ / shares
 3 Months Ended
Sep. 30, 2022
Nov. 09, 2022
Cover [Abstract]    
Entity Central Index Key 0001385818  
Document Type 10-Q/A  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-38247  
Entity Registrant Name AYTU BIOPHARMA, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 47-0883144  
Entity Address, Address Line One 373 Inverness Parkway  
Entity Address, Address Line Two Suite 206  
Entity Address, City or Town Englewood  
Entity Address, State or Province CO  
Entity Address, Postal Zip Code 80112  
City Area Code 720  
Local Phone Number 437-6580  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Entity Listing, Par Value Per Share $ 0.0001  
Trading Symbol AYTU  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   3,121,471
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag true  
Amendment Description Aytu BioPharam, Inc. ("Aytu", "Company", "we", "us", "our") is filing this Amendment No. 1 (this "Amendment") to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "Original Filing"), originally filed on November 14, 2022. With the exception of adjusting the shares to represent the reverse stock split on January 6, 2023 (as described below), this Amendment is presented as of the filing date of the Original Filing and does not reflect events occurring after that date, or modify or update disclosures in any way other than as required to reflect the restatements as described below. Accordingly, this Amendment should be read in conjunction with our filings with the U.S. Securities and Exchange Commission ("SEC") subsequent to the date on which we filed the Original Filing. This Amendment to the Original Filing amends our classification of certain warrants that were previously recorded as equity. These warrants according to generally accepted accounting principles in the United States ("GAAP") should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods are the quarterly unaudited financial statements as of March 31, 2022 and September 30, 2022, and the audited financial statements as of June 30, 2022. SEC Staff Accounting Bulletin No. 99, "Materiality," and FASB, Statement of Financial Accounting Concepts No. 2 "Qualitative Characteristics of Accounting Information" indicate that quantifying and aggregating errors is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual errors are material. The Company evaluated the errors and has determined that the impact was not material for the periods ended March 31, 2022 and June 30, 2022, but was material for the period ended September 30, 2022. The assessment resulted in a restatement of the previously issued financial statements reported in the Original Filing. The balance sheet as at June 30, 2022 included in this Amendment has also been adjusted for the correction of this immaterial error. Financial statements for period ended March 31, 2022 and year ended June 30, 2022 will be adjusted at the time of their reissuance. This Amendment includes the accounting impact in the periods as of and for the three months ended September 30, 2022, and as of June 30, 2022. The change in accounting for the warrants did not have any impact on our liquidity, cash flows, revenues or costs of operating in the affected periods. On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every twenty shares held ("Reverse Stock Split"). All share and per share amounts in this Amendment have been adjusted to reflect the effect of the Reverse Stock Split. We are filing this Amendment to amend and restate the Original Filing with modification as necessary to reflect the restatement. The following items have been amended to reflect the restatement: Part I, Item 1. Consolidated Financial Statements Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Part I, Item 4. Controls and Procedures Part II, Item 1A. Risk Factors Part II, Item 6. Exhibits Refer to Note 2 - Previously Reported Financial Statements to the condensed consolidated financial statements included in this Amendment for additional information and for the summary of the accounting impacts of these adjustments to the Company's financial statements as of and for the period ended September 30, 2022, and as of June 30, 2022.